rawfin.tv
Goldman Sachs Adds Vertex Pharmaceuticals to Conviction Buy List
Marketsstocks🟠 Score 8AI Generated

Goldman Sachs Adds Vertex Pharmaceuticals to Conviction Buy List

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Goldman Sachs has placed Vertex Pharmaceuticals on its highly-regarded conviction buy list, signaling strong confidence in the biotech stock. This upgrade comes with a "buy" rating, suggesting significant upside potential for investors.

Vertex PharmaceuticalsGoldman SachsBiotech StocksAnalyst RatingInvestment Thesis

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks